We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Clinical Status and Optimal Use of New Therapeutic Agents

  • Bruce D. Cheson, MD
Nov 1, 1997
Volume: 
11
Issue: 
11
  • Ovarian Cancer

Over the past few years, several promising new therapeutic agents have been approved by the FDA for the treatment of cancer patients. In addition, other commercially available drugs have been licensed for supplemental indications. The more rapid approval process for oncology drugs has resulted in the widespread use of agents, often before the clinician has sufficient information about their appropriate indications. In this issue of ONCOLOGY, we begin a new series of articles focusing on newly approved agents. The authors of these articles, many of whom were instrumental in the development of the new drugs, have been asked to summarize the clinical experience with and recommended uses for these compounds.

Some of the drugs featured in this issue were discovered during the decades of research devoted to identifying analogs of currently available drugs. These efforts were fueled by the hope that the analogs would exhibit either increased or comparable efficacy and reduced toxicity compared with the parent compound. Gemcitabine (Gemzar), discussed in this issue by Drs. Michael Michael and Malcolm Moore, is one of several nucleoside analogs now in clinical use, but, unlike other commonly used nucleosides (eg, cytarabine, fludarabine [Fludara], and cladribine [Leustatin]), gemcitabine exhibited activity against a broad range of solid tumors in preclinical models. Gemcitabine was recently approved by the FDA for the treatment of pancreatic cancer, not on the basis of its rather limited activity, but primarily because it led to an improvement in disease-related symptoms in approximately one-quarter of patients.

More recently, a considerable effort in drug development has focused on discovering compounds with unique mechanisms of action. The topoisomerase inhibitors represent one such novel class of drugs. Two of these agents, topotecan (Hycamtin) and irinotecan (CPT-11 [Camptosar]), are commercially available. A third, 9-amino-camptothecin, is still undergoing clinical investigation. Topotecan, as described in the paper by Drs. Chris Takimoto and Susan Arbuck, was approved by the FDA 7 years after entering clinical trials, based on the results of a phase III trial in woman with relapsed ovarian cancer. The overall response rate with topotecan in this trial was 21%, which was considered to be at least equivalent to the 15% response rate with paclitaxel (Taxol).

Another newly approved therapeutic agent profiled in this issue is anastrozole (Arimidex). As discussed by Drs. Paul Goss and Lesley Tye, anastrozole is a third-generation inhibitor of estrogen synthetase that is more selective than its predecessor, aminoglutethimide. Phase III trials in postmenopausal women with advanced breast cancer showed an objective tumor response rate of 10.3% with anastrozole, as compared with 7.9% with megestrol acetate, albeit with no difference in time to progression (21 weeks) or overall survival.

Other agents have been approved for use in cancer patients, not because they are therapeutic, but rather, because they improve quality of life or provide some measure of supportive care. As an example, in the fourth paper in this special issue, Dr. Ronald Blum presents data indicating that dexrazoxane (Zinecard) therapy results in a significant reduction in the frequency of anthracycline-induced cardiotoxicity.

There are many unresolved issues surrounding the development of new antineoplastic drugs. When they are administered to patients with relapsed or refractory tumors, it is with palliative intent. Response rates and duration of response will likely be greater when patients receive these drugs as part of their initial treatment program. However, it is obvious that, even as front-line treatment, none of these drugs will be curative when administered as single agents. Therefore, one of the most important unanswered questions is how to best develop rational combinations with other active drugs that will result in increased efficacy compared with the activity of each single component. Too often, agents are combined simply because each exhibits some activity against a particular tumor type. The seemingly never-ending array of drug combinations and permutations generated by the empiric approach has rarely been successful in significantly enhancing efficacy, and is not an efficient use of time and resources.

So, how can we better direct our efforts to make significant advances, rather than small incremental steps, in anticancer therapy? The first step should be aimed at gaining a better characterization of the genetic, molecular, and immunologic lesions resulting in malignancy and tumor progression. As these therapeutic targets are identified, specific therapeutic strategies can be directed at them.

Second, and equally important, should be a commitment to increase accrual of patients to important clinical trials. Only through the close interaction between laboratory scientists and clinical researchers, and the expedient testing of new therapies, will we be able to achieve the goal of cure.

Related Articles

  • Promising Personalized Ovarian Cancer Vaccine Induces Immune Responses
  • FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
  • PARP-7 Amplification Mutations Linked to Prolonged Survival in Ovarian Cancer
  • Trial Participation May Offset Disparities in Ovarian Cancer Care
  • Despite Evolving Treatment for Ovarian Cancer, Late Diagnosis Remains a Challenge

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.